← Retour à toutes les réponses
Does a liver transplant cure Wilson disease, or do I still need treatment?
A liver transplant corrects the underlying copper metabolism defect and cures the liver disease — after a successful transplant, you no longer need copper-lowering drugs, but you will take lifelong immunosuppression.
A liver transplant is as close to a cure for Wilson disease as medicine currently offers. The transplanted liver carries a normally functioning copy of the ATP7B gene, which means it will export copper the way a healthy liver should — and the endless battle against copper accumulation effectively ends.1 You will not need penicillamine, trientine, or zinc to control copper after a successful transplant.
That is the big picture. The finer points — what still requires attention, what may not fully recover, and who benefits most — are worth understanding before or after transplant.
Why transplant corrects the copper problem
Wilson disease is caused by a defective gene in liver cells that prevents them from exporting excess copper. When you receive a donor liver with a working ATP7B gene, those new liver cells do the job correctly. Copper metabolism normalizes within weeks to months of transplant — urine copper excretion drops, ceruloplasmin often rises toward normal, and the accumulation of free copper in blood and other organs stops.2
Studies tracking copper parameters in Wilson disease patients after transplant consistently show normalization without the need for ongoing chelation therapy or zinc supplementation.3 This is different from most other causes of liver transplantation, where the liver disease recurs or continues in some form. Wilson disease does not recur in a transplanted liver.
What you will still need: immunosuppression
Transplanting an organ from another person requires suppressing your immune system so it does not attack the donor organ. This is lifelong — there is currently no safe way to stop immunosuppressive medications in most transplant recipients. Common regimens include:
- Calcineurin inhibitors (tacrolimus or cyclosporine) — the backbone of most transplant immunosuppression
- Mycophenolate — often added to reduce rejection risk
- Corticosteroids — sometimes used for the first year, then tapered
These medications come with their own monitoring requirements and long-term considerations (kidney function, infection risk, blood pressure, bone health, and cancer screening). Your transplant team will manage this, but understanding it helps set expectations: transplant is not a return to life with no medical oversight. It is trading one monitoring program for another — arguably less burdensome, but ongoing.4
What may or may not improve after transplant
Liver disease
Transplant resolves acute liver failure and prevents progression of cirrhosis. For people who receive a transplant during or just after acute liver failure (which can be life-threatening in Wilson disease), survival rates are good when transplant happens quickly enough.2
Neurological symptoms
This is more complicated. Neurological Wilson disease — tremor, slurred speech, swallowing difficulties, dystonia, movement problems — has a variable response to transplant. Several studies show that neurological symptoms continue to improve for months to years after transplant in many patients, as the brain gradually recovers from copper toxicity.5 Some patients have experienced dramatic neurological recovery after transplant, including cases where severe neurological disease was the primary reason for referral.
However, the evidence is not uniformly positive. A meaningful minority of patients do not improve neurologically after transplant, and in some case series, neurological status did not change significantly. The reason is not fully understood — it may relate to the degree of structural brain damage that accumulated before transplant, or to the duration of untreated neurological disease.6
This is one reason neurological Wilson disease is not a straightforward transplant indication. The 2022 AASLD Practice Guidance and the EASL guidelines reserve transplant primarily for liver failure, severe or decompensated cirrhosis, and rare cases of neurological Wilson disease that are refractory to medical treatment.34 If your case is primarily neurological, the decision about transplant requires a very careful specialist conversation.
Psychiatric symptoms
Similarly to neurological symptoms, psychiatric symptoms — depression, anxiety, cognitive changes — may improve after transplant as copper toxicity resolves, but this is not guaranteed. See Will my depression improve once copper levels come down? for the broader picture of psychiatric recovery.
What is the long-term outlook after transplant?
Transplant outcomes for Wilson disease are generally favorable compared with many other conditions:
| Consideration | Post-transplant status |
|---|---|
| Copper-lowering drugs needed | No |
| Copper monitoring | Typically initial monitoring, then can be discontinued |
| Immunosuppression | Yes, lifelong |
| Liver disease recurrence | Does not recur in the new liver |
| Diet restrictions | No copper restriction needed |
| Alcohol | Still not recommended (general transplant guidance) |
| Neurological improvement | Variable; often gradual over months to years |
Long-term survival data for Wilson disease patients after transplant are encouraging — a registry analysis from Shiraz, Iran involving over 100 cases showed good long-term outcomes at specialized centers.2 The major risks in the long term are those shared by all transplant recipients: rejection, infection, medication side effects, and malignancy.
Who is a transplant candidate?
Transplant is not the first treatment for Wilson disease — it is reserved for specific situations:34
- Acute liver failure (fulminant Wilson disease) — this is a medical emergency and the main scenario where transplant is urgent
- Decompensated cirrhosis not responding to medical treatment
- Progressive cirrhosis with sufficient decline in liver function
- Selected cases of neurological Wilson disease refractory to medical therapy (criteria not fully standardized)
For patients newly diagnosed who are stable enough for medical therapy, the evidence strongly supports starting chelation therapy and zinc first. Transplant is major surgery with real risks and lifelong consequences — it is the right answer for some, not for everyone.
After transplant: staying well
The years after transplant involve regular appointments with a transplant hepatologist, medication management, and standard preventive health care. Many transplant recipients go on to live full, active lives. You may find the medications overview useful for context on what you are leaving behind, and the depression and anxiety post if you are processing the emotional weight of such a major medical event.
This post is patient education, not medical advice. The decision about liver transplantation is highly individual and must be made in close consultation with a transplant hepatologist and the full transplant team.
References
-
Czlonkowska, Anna, Tomasz Litwin, Petr Dusek, et al. “Wilson Disease.” Nature Reviews Disease Primers 4, no. 1 (2018): 21. https://doi.org/10.1038/s41572-018-0024-5. ↩
-
Aksoy, Fuat, İbrahim Ethem Arslan, Taner Ozgur, et al. “Does Liver Transplant Improve Neurological Symptoms in Wilson Disease? Report of 24 Cases.” Experimental and Clinical Transplantation 20, no. 11 (2022): 1009–1015. https://doi.org/10.6002/ect.2022.0206. ↩↩↩
-
Schilsky, Michael L., Kris V. Kowdley, Brendan M. McGuire, et al. “A Multidisciplinary Approach to the Diagnosis and Management of Wilson Disease: 2022 Practice Guidance from the American Association for the Study of Liver Diseases.” Hepatology 77, no. 4 (2023): 1428–1455. https://doi.org/10.1002/hep.32801. ↩↩↩
-
European Association for Study of Liver. “EASL Clinical Practice Guidelines: Wilson’s Disease.” Journal of Hepatology 56, no. 3 (2012): 671–685. https://doi.org/10.1016/j.jhep.2011.11.007. ↩↩↩
-
Stracciari, Andrea, Antonio Tempestini, Anna Borghi, and Raffaele Guarino. “Effect of Liver Transplantation on Neurological Manifestations in Wilson Disease.” Archives of Neurology 57, no. 3 (2000): 384–386. https://doi.org/10.1001/archneur.57.3.384. ↩
-
Medici, Valentina, Vittorio G. Mirante, Luisa R. Fassati, et al. “Liver Transplantation for Wilson’s Disease: The Burden of Neurological and Psychiatric Disorders.” Liver Transplantation 11, no. 9 (2005): 1056–1063. https://doi.org/10.1002/lt.20486. ↩
-
Alkhouri, Naim, and Tarun Mullick. “Wilson Disease: Review of Diagnosis and Management.” Hepatology Communications 7, no. 8 (2023): e0150. https://doi.org/10.1097/HC9.0000000000000150. ↩
-
Litwin, Tomasz, Anna Członkowska, and Łukasz Smoliński. “Early Neurological Worsening in Wilson Disease: The Need for an Evidence-Based Definition.” Journal of Hepatology 79, no. 4 (2023): 1003–1012. https://doi.org/10.1016/j.jhep.2023.06.009. ↩
Ceci est de l'information destinée aux patients, pas un conseil médical. Consultez toujours votre propre équipe soignante pour les décisions concernant votre santé.